Cookies on the KCI website
We use cookies to improve your browsing experience on our website. Please visit Privacy Policy our for more information about cookies and how we use them. We recommend you to accept the use of cookies for better navigation.
Tilgængelighed | Sitemap | Kontakt os | Kundeservice Telefon +45 3990 0180
Danmark Change Country
Startside  |  Lidelser  |  Produkter  |  Klinisk evidens  |  For patienter  |  Kundeservice
Her er du: Startside > Nyheder og presse > Acelity Announces Expansion of Prevena™ Therapy Portfolio with Addition of Shorter Peel & Place™ System

Acelity Announces Expansion of Prevena™ Therapy Portfolio with Addition of Shorter Peel & Place™ System

Udgivet : 8 Oktober 2015
KCI, Leader in Advanced Wound Care Solutions

New system allows clinicians to better manage smaller incisions and anatomically challenging areas


SAN ANTONIO, October 8, 2015 – Acelity announced today that it is extending its Prevena™ Therapy portfolio with the addition of a new, shorter Peel & Place™ System. The dressing in the Peel & Place™ - 13 System is identical to the existing system except for its shorter length and is designed for the management of linear incisions up to 13 centimeters in length. The Prevena™ Peel & Place™ - 13 System is now available in the United States and Europe, and expanded availability globally is anticipated in January 2016.


This expansion of the Prevena™ Peel & Place™ product line enables a surgeon to target negative pressure therapy for incisions in anatomically challenging areas of the body. The new 13cm dressing is provided either separately or in combination with the portable Prevena™ 125 Therapy Unit that provides negative pressure therapy in a small, easy to operate device that can transition home with the patient. This system will make Prevena™ Therapy available to a wider range of incisions.


“The smaller profile of the Prevena™ Peel & Place™ -13 System will be instrumental in helping deliver negative pressure therapy for patients whose incisions are located in challenging areas of the body,” said Mahmoud B Malas, M.D., Director of Endovascular Surgery, Johns Hopkins Bayview Medical Center. “Surgeons now have a new option designed specifically for smaller incisions to help them better manage patient outcomes.”


“Reducing surgical site complications is critically important to hospitals and health systems around the world,” said Ron Silverman, M.D., Chief Medical Officer, Acelity. “This expansion provides surgeons and additional patient populations with the power and clinical benefits of Prevena™ Therapy in the management of closed surgical incisions, as demonstrated by a growing body of evidence.”

The Prevena™ Incision Management System is the first powered negative pressure product designed specifically for management of closed surgical incisions that continue to drain following sutured or stapled closure. The Prevena™ System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material. The Prevena System has been evaluated clinically in a number of surgeries at risk of complications, such as sternotomy, cesareans, hysterectomies, orthopedic and vascular groin incisions, all with positive clinical outcomes.*

*Bibliography available upon request.

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,700 people around the world.


For more information, contact:

Kathryn Skeen
Corporate Communications
Phone: +1-210-882-2067

    Caleb Moore
Investor Relations
Phone: +1-210-255-6433


  • Del på Facebook
  • Del på Twitter
  • Besøg vores side på YouTube

Vigtig meddelelse til patienter

Juridisk information | Politik til beskyttelse af personlige oplysninger | Kontakt os

© 1998 – 2013 KCI Li.ensing, Inc. Alle rettigheder forbeholdes.    DSL# 09-03-193.DK
Oplysningerne indeholdt på dette websted er udelukkende udarbejdet og beregnet til visning i Danmark. Dette websted indeholder oplysninger om produkter, som kan være delvist tilgængelige afhængigt af det aktuelle land, og kan i et sådant tilfælde være omfattet af godkendelse eller manglende godkendelse samt markedstilladelse fra gældende myndighed i henhold til indikationer og restriktioner i de aktuelle lande.